Research programme: anti-midkine antibodies - Cellmid

Drug Profile

Research programme: anti-midkine antibodies - Cellmid

Alternative Names: CAB 101; CAB 102; Hu91- Cellmid; IP10; IP13; IP14; IP9

Latest Information Update: 13 Jul 2016

Price : $50

At a glance

  • Originator Cellmid
  • Class Monoclonal antibodies
  • Mechanism of Action MDK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 13 Jul 2016 Preclinical development is ongoing in Australia
  • 02 Feb 2010 This programme is available for licensing (http://www.cellmid.com.au)
  • 02 Feb 2010 Preclinical trials in Cancer in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top